Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $562K fell 12.3% year over year, behind the -9.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +21.9% a year.
Context
- Depreciation & amortization amounted to 33.9% of revenue in FY2025.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.3% toward the trailing-twelve-month pace of -9.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.54M USD
- Year-over-year change
- -0.7%
- 4-year CAGR
- +29.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.54M | -0.7% |
| FY2024 | 2024-12-31 | 2.56M | -27.7% |
| FY2023 | 2023-12-31 | 3.54M | +152.0% |
| FY2022 | 2022-12-31 | 1.41M | +55.1% |
| FY2021 | 2021-12-31 | 906K | — |
Depreciation & Amortization vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's LTM Sep 2026 depreciation & amortization of $2.32M is the 7th largest of the 11 companies compared; the peer median is $10.98M.
- Its year-over-year change of -9.6% is the 7th highest of 10, against a peer median of +7.4%.
- Over three fiscal years its annual growth of +21.9% compares with a peer median of +12.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $718.57M | +4.8% | +3.4% | 15.2% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $83.6M | +181.5% | +24.5% | 2.3% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $12.02M | -12.0% | +79.7% | 1.1% | |
| LTM Jun 2026 | $9.94M | +16.8% | +27.2% | 1.3% | |
| LTM Sep 2026 | $2.32M | -9.6% | +21.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding XENE) | $10.98M | +7.4% | +12.6% | 5.0% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| Deferred Income Tax | 58K | (44K) | (292K) | (8.86M) | (3.2M) |
| Stock-Based Compensation | 10.02M | 20.38M | 32.37M | 50.72M | 53.71M |
| Change in Working Capital | (2.65M) | (676K) | 5.64M | 5.71M | 4.36M |
| Accounts Receivables | (459K) | 1.76M | 130K | (614K) | 104K |
| Inventory | (2.97M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.97M | 8.06M | 3.93M | 8.53M | 5.51M |
| Other Working Capital | (2.19M) | (10.5M) | 1.57M | (2.2M) | (1.26M) |
| Other Non-Cash Items | 1.05M | 5.88M | (4.19M) | 2.82M | 9.38M |
| Operating Cash Flow | (69.5M) | (98.43M) | (145.33M) | (181.39M) | (279.12M) |
| Capital Expenditures | (2.05M) | (2.89M) | (5.62M) | (3.08M) | (799K) |
| Acquisitions (Net) | (144.75M) | 296M | 0 | 0 | 0 |
| Purchases of Investments | (389.47M) | (551.14M) | (793.91M) | (532.27M) | (355.66M) |
| Sales of Investments | 144.75M | 258.03M | 682.35M | 700.34M | 574.45M |
| Other Investing Activities | 144.75M | (296M) | 0 | 0 | 0 |
| Investing Cash Flow | (246.77M) | (296M) | (117.17M) | 165M | 218M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 447.28M | 277.77M | 353.49M | 12.08M | 117.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 260K | 705K | 35K | 47K | 0 |
| Financing Cash Flow | 447.54M | 278.47M | 353.52M | 12.13M | 117.11M |
| Effect of Forex Changes | (592K) | (2.48M) | 376K | (1.67M) | 458K |
| Net Change in Cash | 130.68M | (118.45M) | 91.4M | (5.93M) | 56.45M |
| Free Cash Flow | (71.55M) | (101.32M) | (150.94M) | (184.46M) | (279.92M) |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.